Human Squamous Cell Carcinoma antigen CLIA Kit

Description

​​​​​​​

Background

​​​​​​​The Human Squamous Cell Carcinoma antigen CLIA Kit is designed, developed, and produced for the quantitative measurement of human SCC levels in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of SCC. Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with magnetic particles antibody. The magnetic particles capture the SCC in the form of “magnetic particles–SCC antibody–SCC–acridinium ester SCC antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 or ECL 25 analyzer. The relative light units (RLU) are proportional to the concentration of a SCC in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum SCC concentration.

Selected Literature

​​​​​​​1.Chen Y M, Wang L, Zhong L H, et al. Application of tumor markers in the early diagnosis of ovarian cancer (J). Current Medicine,2012; 18 (20) : 12-3.
​​​​​​​2.Chen Jing-jing, Chen Jian-min, Sun Quan. Clinical significance of CEA, CK19 and SCC in diagnosis of lung cancer [J]. Modern immunology, 2017,37 (3) : 22.
3.Zhu Lin,GUOGuang-hong,Evaluation of ChemiluminescentMicroparticle Immunoassay for Detection of Squamous Cell Carcinoma Antigen,Labeled Immunoassays and Clinical Medicine,2016, 23(10).​​​​​​

For research use only. Not for use in diagnostics procedures.